Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Capsaicin · 1 trial · 1 indication
Change from pre-capsaicin DBF adjusting for vehicle at 30 minutes is reported. The capsaicin induced dermal blood flow (DBF) was measured by laser Doppler imaging (LDI).
The mean Plasma Calcitonin Gene-Related Peptide levels were reported.
| Arm | Type | Description |
|---|---|---|
| Capsaicin | EXPERIMENTAL | Single topical dose of capsaicin |
| Name | Type | Description |
|---|---|---|
| Capsaicin | DRUG | Administered topically |
Inclusion Criteria: * Participants with migraine who have previously participated in study NTC02163993 and received one of the selected doses of galcanezumab or placebo * Have suitable skin characteristics for the dermal capsaicin challenge Exclusion Criteria: * Have a history of significant alle...
Capsaicin is being studied by Eli Lilly and Company as an investigational treatment for migraine disorders. It is in Phase 1 clinical development, with one completed early Phase 1 biomarker study in participants with migraine. It is not an approved migraine therapy.
Capsaicin targets TRPV1, the transient receptor potential vanilloid 1 receptor. It acts as a TRPV1 opener, meaning it activates this receptor. TRPV1 is a pain and sensory signaling ion channel, and modulating it is the basis for studying Capsaicin in migraine.
Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY, is the developer of Capsaicin for migraine disorders. The company is responsible for its clinical development program in this indication.
Capsaicin is in Phase 1 development for migraine disorders. The program includes one completed early Phase 1 trial. As an investigational small molecule, it has not been approved for any migraine indication.
Capsaicin has been evaluated in one completed clinical trial, NCT02766517, titled Biomarker Study in Participants With Migraine. The early Phase 1 study enrolled 37 participants in the United States. It was an uncontrolled study without randomization or double blinding.